An antisense oligonucleotide-based strategy to ameliorate cognitive dysfunction in the 22q11.2 Deletion Syndrome.

Importantly, most of our t-tests yielded highly significant results (p < 0.001 or p < 0.01), reinforcing the robustness of our findings.

also in 132,142 other papers